CC
ESPR

Caxton Corporation’s Esperion Therapeutics ESPR Stock Holding History

Caxton Corporation’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,671
Closed -$340K – 21
2015
Q1 		$340K Buy
+3,671
New +$237K 0.41% 9

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Caxton Corporation's ESPR Position: Q2 2015 in Review

Caxton Corporation sold out of Esperion Therapeutics (ESPR) in Q2 2015, closing a stake of 3,671 shares — an estimated $340K sold.

Caxton Corporation first reported a position in ESPR in Q1 2015 and held it in 1 quarter. The position peaked at $340K in Q1 2015. 151 funds tracked by Wall St. Rank hold ESPR as of Q2 2015.

  • Caxton Corporation reported no remaining Esperion Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Caxton Corporation sold 3,671 Esperion Therapeutics shares in Q2 2015, an estimated $340K.
  • Caxton Corporation first reported a position in Esperion Therapeutics in Q1 2015 and held it in 1 quarter.
  • Caxton Corporation's Esperion Therapeutics position peaked at $340K in Q1 2015.
  • 151 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2015.

Based on Caxton Corporation's 13F filing for Q2 2015, filed 14 Aug 2015.